355 related articles for article (PubMed ID: 33155524)
1. Computationally validated SARS-CoV-2 CTL and HTL Multi-Patch vaccines, designed by reverse epitomics approach, show potential to cover large ethnically distributed human population worldwide.
Srivastava S; Verma S; Kamthania M; Agarwal D; Saxena AK; Kolbe M; Singh S; Kotnis A; Rathi B; Nayar SA; Shin HJ; Vashisht K; Pandey KC
J Biomol Struct Dyn; 2022 Mar; 40(5):2369-2388. PubMed ID: 33155524
[TBL] [Abstract][Full Text] [Related]
2. Novel "GaEl Antigenic Patches" Identified by a "Reverse Epitomics" Approach to Design Multipatch Vaccines against NIPAH Infection, a Silent Threat to Global Human Health.
Srivastava S; Kolbe M
ACS Omega; 2023 Sep; 8(35):31698-31713. PubMed ID: 37692250
[TBL] [Abstract][Full Text] [Related]
3. Vaccines Targeting Numerous Coronavirus Antigens, Ensuring Broader Global Population Coverage: Multi-epitope and Multi-patch Vaccines.
Srivastava S; Chatziefthymiou SD; Kolbe M
Methods Mol Biol; 2022; 2410():149-175. PubMed ID: 34914046
[TBL] [Abstract][Full Text] [Related]
4. Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2.
Tahir Ul Qamar M; Shahid F; Aslam S; Ashfaq UA; Aslam S; Fatima I; Fareed MM; Zohaib A; Chen LL
Infect Dis Poverty; 2020 Sep; 9(1):132. PubMed ID: 32938504
[TBL] [Abstract][Full Text] [Related]
5. An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study.
Yang Z; Bogdan P; Nazarian S
Sci Rep; 2021 Feb; 11(1):3238. PubMed ID: 33547334
[TBL] [Abstract][Full Text] [Related]
6. Design of novel multi-epitope vaccines against severe acute respiratory syndrome validated through multistage molecular interaction and dynamics.
Srivastava S; Kamthania M; Kumar Pandey R; Kumar Saxena A; Saxena V; Kumar Singh S; Kumar Sharma R; Sharma N
J Biomol Struct Dyn; 2019 Oct; 37(16):4345-4360. PubMed ID: 30457455
[TBL] [Abstract][Full Text] [Related]
7. Whole proteome screening and identification of potential epitopes of SARS-CoV-2 for vaccine design-an immunoinformatic, molecular docking and molecular dynamics simulation accelerated robust strategy.
Ezaj MMA; Junaid M; Akter Y; Nahrin A; Siddika A; Afrose SS; Nayeem SMA; Haque MS; Moni MA; Hosen SMZ
J Biomol Struct Dyn; 2022 Sep; 40(14):6477-6502. PubMed ID: 33586620
[TBL] [Abstract][Full Text] [Related]
8. A rational design of a multi-epitope vaccine against SARS-CoV-2 which accounts for the glycan shield of the spike glycoprotein.
Martin WR; Cheng F
J Biomol Struct Dyn; 2022 Sep; 40(15):7099-7113. PubMed ID: 33715598
[TBL] [Abstract][Full Text] [Related]
9. Structural Basis for Designing Multiepitope Vaccines Against COVID-19 Infection: In Silico Vaccine Design and Validation.
Srivastava S; Verma S; Kamthania M; Kaur R; Badyal RK; Saxena AK; Shin HJ; Kolbe M; Pandey KC
JMIR Bioinform Biotechnol; 2020; 1(1):e19371. PubMed ID: 32776022
[TBL] [Abstract][Full Text] [Related]
10.
Devi A; Chaitanya NSN
J Biomol Struct Dyn; 2021 Nov; 39(18):6903-6917. PubMed ID: 32772892
[TBL] [Abstract][Full Text] [Related]
11. Vaccinomic approach for novel multi epitopes vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Almofti YA; Abd-Elrahman KA; Eltilib EEM
BMC Immunol; 2021 Mar; 22(1):22. PubMed ID: 33765919
[TBL] [Abstract][Full Text] [Related]
12. A vaccine built from potential immunogenic pieces derived from the SARS-CoV-2 spike glycoprotein: A computational approximation.
Marchan J
J Immunol Methods; 2022 Mar; 502():113216. PubMed ID: 35007561
[TBL] [Abstract][Full Text] [Related]
13. Designing a multi-epitope vaccine against SARS-CoV-2: an immunoinformatics approach.
Samad A; Ahammad F; Nain Z; Alam R; Imon RR; Hasan M; Rahman MS
J Biomol Struct Dyn; 2022 Jan; 40(1):14-30. PubMed ID: 32677533
[TBL] [Abstract][Full Text] [Related]
14. Multi-epitope vaccine against SARS-CoV-2 applying immunoinformatics and molecular dynamics simulation approaches.
Jyotisha ; Singh S; Qureshi IA
J Biomol Struct Dyn; 2022 Apr; 40(7):2917-2933. PubMed ID: 33164664
[TBL] [Abstract][Full Text] [Related]
15. Immuno-Informatics Quest against COVID-19/SARS-COV-2: Determining Putative T-Cell Epitopes for Vaccine Prediction.
Akhtar N; Joshi A; Singh B; Kaushik V
Infect Disord Drug Targets; 2021; 21(4):541-552. PubMed ID: 32957905
[TBL] [Abstract][Full Text] [Related]
16. Exploring the structural basis to develop efficient multi-epitope vaccines displaying interaction with HLA and TAP and TLR3 molecules to prevent NIPAH infection, a global threat to human health.
Srivastava S; Verma S; Kamthania M; Saxena AK; Pandey KC; Pande V; Kolbe M
PLoS One; 2023; 18(3):e0282580. PubMed ID: 36920996
[TBL] [Abstract][Full Text] [Related]
17.
Mitra D; Pandey J; Jain A; Swaroop S
J Biomol Struct Dyn; 2022 Jul; 40(11):5189-5202. PubMed ID: 33403946
[TBL] [Abstract][Full Text] [Related]
18. Designing an efficient multi-epitope vaccine displaying interactions with diverse HLA molecules for an efficient humoral and cellular immune response to prevent COVID-19 infection.
Mahapatra SR; Sahoo S; Dehury B; Raina V; Patro S; Misra N; Suar M
Expert Rev Vaccines; 2020 Sep; 19(9):871-885. PubMed ID: 32869699
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 coronavirus vaccine T cell epitope prediction analysis based on distributions of HLA class I loci (HLA-A, -B, -C) across global populations.
Cun Y; Li C; Shi L; Sun M; Dai S; Sun L; Shi L; Yao Y
Hum Vaccin Immunother; 2021 Apr; 17(4):1097-1108. PubMed ID: 33175614
[TBL] [Abstract][Full Text] [Related]
20. Scrutinizing the SARS-CoV-2 protein information for designing an effective vaccine encompassing both the T-cell and B-cell epitopes.
Jain N; Shankar U; Majee P; Kumar A
Infect Genet Evol; 2021 Jan; 87():104648. PubMed ID: 33264668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
